OXiGENE Announces Presentation at BIO CEO Conference on February 11th
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer, announced that Peter Langecker, M.D., PhD.,
President and Chief Executive Officer, will provide a corporate overview at
the 16th annual BIO CEO & Investor conference on February 11, 2014 at 11:00 am
ET at the Waldorf Astoria Hotel in New York City.
To listen to a live or an archived version of the audio webcast, please log on
to the Company's website, www.oxigene.com. Under the "Investors" tab, select
the link to "Events & Presentations." A replay of the webcast will be
available one hour after the conclusion of the live event.
OXiGENE is a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer. The Company's major focus is developing vascular
disrupting agents (VDAs) that selectively disrupt abnormal blood vessels
associated with solid tumor progression. OXiGENE is dedicated to leveraging
its intellectual property and therapeutic development expertise to bring
life-extending and life-enhancing medicines to patients.
CONTACT: Investor and Media Contact:
Press spacebar to pause and continue. Press esc to stop.